Table of Content

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary


2. Strategic Recommendations


3. Rheumatoid Arthritis Market: Product Outlook


4. Global Rheumatoid Arthritis Market: Sizing and Forecast

4.1 Global Rheumatoid Arthritis Market Size, By Value, 2016-2026

4.2 Impact of COVID-19 on Global Rheumatoid Arthritis Market


5. Global Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis

5.1 Competitive Scenario of Global Rheumatoid Arthritis Market: By Drug Type

5.1.1 NSAID(non-steroidal anti-inflammatory drugs) - Market Size and Forecast (2016-2026)

5.1.2 DMARD’S(Disease-modifying anti-rheumatic drug) - Market Size and Forecast (2016-2026)

5.1.3 Corticosteroids- Market Size and Forecast (2016-2026)

5.1.4 Others - Market Size and Forecast (2016-2026)

5.2 Competitive Scenario of Global Rheumatoid Arthritis Market: By Treatment

5.2.1 Tendon Repair - Market Size and Forecast (2016-2026)

5.2.2 Joint Fusion- Market Size and Forecast (2016-2026)

5.2.3 Joint Replacement- Market Size and Forecast (2016-2026)

5.2.4 Others - Market Size and Forecast (2016-2026)

5.3 Competitive Scenario of Global Rheumatoid Arthritis Market: By Diagnosis

5.3.1 CRP(Creative Protein Test) - Market Size and Forecast (2016-2026)

5.3.2 ESR (Erythrocyte Sedimentation Rate)- Market Size and Forecast (2016-2026)

5.3.3 Others - Market Size and Forecast (2016-2026)


6. Global Rheumatoid Arthritis Market: Regional Analysis

6.1 Competitive Scenario of Global Rheumatoid Arthritis Market: By Region


7. Americas Rheumatoid Arthritis Market: Segmentation (By Drug Type, By Treatment, By Diagnosis)

7.1 Americas Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

7.2 Americas Rheumatoid Arthritis Market - Prominent Companies

7.3 Market Segmentation By Drug Type (DMARD?s, NSAID, Corticosteroids and Others)

7.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)

7.5 Market Segmentation By Diagnosis (CRP, ESR and Others)

7.6 Americas Rheumatoid Arthritis Market: Country Analysis

7.7 Market Opportunity Chart of Americas Rheumatoid Arthritis Market - By Country, By Value, 2026

7.8 Competitive Scenario of Americas Rheumatoid Arthritis Market: By Country

7.9 United States Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

7.10 United States Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

7.11 Canada Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

7.12 Canada Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)


8. Europe Rheumatoid Arthritis Market: An Analysis (2016-2026)

8.1 Europe Rheumatoid Arthritis Market: Size and Forecast (2016-2026)

8.2 Europe Rheumatoid Arthritis Market - Prominent Companies

8.3 Market Segmentation By Drug Type (DMARD?s, NSAID, Corticosteroids and Others)

8.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)

8.5 Market Segmentation By Diagnosis (CRP, ESR and Others)

8.6 Europe Rheumatoid Arthritis Market: Country Analysis

8.7 Market Opportunity Chart of Europe Rheumatoid Arthritis Market - By Country, By Value, 2026

8.8 Competitive Scenario of Europe Rheumatoid Arthritis Market: By Country

8.9 Germany Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.10 Germany Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8.11 United Kingdom Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.12 United Kingdom Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8.13 France Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.14 France Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8.15 Italy Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.16 Italy Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8.17 Spain Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.18 Spain Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)


9. Asia Pacific Rheumatoid Arthritis Market: An Analysis (2016-2026)

9.1 Asia Pacific Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

9.2 Asia Pacific Rheumatoid Arthritis Market - Prominent Companies

9.3 Market Segmentation By Drug Type (DMARDs, NSAID, Corticosteroids and Others)

9.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)

9.5 Market Segmentation By Diagnosis (CRP, ESR and Others)

9.6 Asia Pacific Rheumatoid Arthritis Market: Country Analysis

9.7 Market Opportunity Chart of Asia Pacific Rheumatoid Arthritis Market - By Country, By Value, 2026

9.8 Competitive Scenario of Asia Pacific Rheumatoid Arthritis Market: By Country

9.9 China Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

9.10 China Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

9.11 Japan Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

9.12 Japan Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

9.13 India Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

9.14 India Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)


10. Global Rheumatoid Arthritis Market Dynamics

10.1 Drivers

10.2 Restraints

10.3 Trends


11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Drug Type, 2026

11.2 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Treatment, 2026

11.3 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Diagnosis, 2026

11.4 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Region, 2026

12. Competitive Landscape

12.1 Product Pipeline of Leading Rheumatoid Arthritis Companies

12.2 Market Share Analysis

13. Company Analysis

13.1 Merck KGaA

13.2 Sanofi

13.3 Eli Lilly Company

13.4 Amgen Inc.

13.5 Bristol-Mayor Squibb

13.6 F. Hoffman-La Roche Ltd

13.7 Johnson & Johnson

13.8 Cipla

13.9 Pfizer

13.10 Galapagos NV

13.11 Gilead Sciences



List of Figures

List of Figures

Figure 1: Global Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 2: Global Research and Development (% of GDP), 2015-2018

Figure 3: GDP per Capita Growth (annual %), 2015-2019

Figure 4: World Population 65 Years & Above (% of Total), 2015-2019

Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 6: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 7: Global Rheumatoid Arthritis Market- By Drug Type Market Share, 2020 & 2026

Figure 8: Global Rheumatoid Arthritis Market- By NSAID, By Value (USD Million), 2016-2026

Figure 9: Global Rheumatoid Arthritis Market- By DMARD?S, By Value (USD Million), 2016-2026

Figure 10: Global Rheumatoid Arthritis Market- By Corticosteroids, By Value (USD Million), 2016-2026

Figure 11: Global Rheumatoid Arthritis Market- By Others, By Value (USD Million), 2016-2026

Figure 12: Global Rheumatoid Arthritis Market- By Treatment Market Share, 2020 & 2026

Figure 13: Global Rheumatoid Arthritis Market- By Tendon Repair, By Value (USD Million), 2016-2026

Figure 14: Global Rheumatoid Arthritis Market- By Joint Fusion, By Value (USD Million), 2016-2026

Figure 15: Global Rheumatoid Arthritis Market- By Joint Replacement, By Value (USD Million), 2016-2026

Figure 16: Global Rheumatoid Arthritis Market- By Others, By Value (USD Million), 2016-2026

Figure 17: Global Rheumatoid Arthritis Market- By Diagnosis Market Share, 2020 & 2026

Figure 18: Global Rheumatoid Arthritis Market- By CRP, By Value (USD Million), 2016-2026

Figure 19: Global Rheumatoid Arthritis Market- By ESR, By Value (USD Million), 2016-2026

Figure 20: Global Rheumatoid Arthritis Market- By Others, By Value (USD Million), 2016-2026

Figure 21: Global Rheumatoid Arthritis Market- By Region Market Share, 2020 & 2026

Figure 22: Americas Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 23: Americas Biologic medicine share of total pharmaceutical sales, 2018 (Share of sales in %)

Figure 24: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 25: North America Population ages 65 and above (% of total Population), 2016-2020

Figure 26: Americas Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 27: Americas Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 28: Americas Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 29: Market Opportunity Chart of Americas Rheumatoid Arthritis Market- By Country, By Value (2016-2026)

Figure 30: Americas Rheumatoid Arthritis Market- By Country Market Share, 2020 & 2026

Figure 31: United States Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 32: United States Current health expenditure per capita (current USD), 2014-18

Figure 33: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 34: United States Population aged 65 and above (% of total Population), 2016-2020

Figure 35: United States Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 36: United States Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 37: United States Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 38: Canada Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 39: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 40: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 41: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 42: Canada Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 43: Canada Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 44: Canada Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 45: Europe Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 46: Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 47: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 48: European Countries Population ages 65 and above (% of total Population), 2020

Figure 49: Europe Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 50: Europe Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 51: Europe Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 52: Market Opportunity Chart of Europe Rheumatoid Arthritis Market- By Country, By Value (2016-2026)

Figure 53: Europe Rheumatoid Arthritis Market- By Country Market Share, 2020 & 2026

Figure 54: Germany Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 55: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 56: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 57: Germany Urban population, 2015-2019 (In %)

Figure 58: Germany Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 59: Germany Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 60: Germany Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 61: United Kingdom Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 62: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 63: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 64: United Kingdom Population ages 65 and above (% of total Population), 2016-20

Figure 65: United Kingdom Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 66: United Kingdom Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 67: United Kingdom Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 68: France Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 69: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 70: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 71: France Population ages 65 and above (% of Total Population), 2016-20

Figure 72: France Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 73: France Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 74: France Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 75: Italy Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 76: Italy Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 77: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 78: Italy Population ages 65 and above (% of Total Population), 2016-20

Figure 79: Italy Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 80: Italy Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 81: Italy Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 82: Spain Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 83: Spain Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 84: Spain Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 85 Spain Urban population, 2016-2020 (In %)

Figure 86: Spain Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 87: Spain Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 88: Spain Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 89: Asia Pacific Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 90: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 91: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 92: Asia Pacific Population ages 65 and above, by Countries (% of Total Population), 2020

Figure 93: Asia Pacific Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 94: Asia Pacific Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 95: Asia Pacific Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 96: Market Opportunity Chart of APAC Rheumatoid Arthritis Market- By Country, By Value (Year-2026)

Figure 97: APAC Rheumatoid Arthritis Market- By Country Market Share, 2020 & 2026

Figure 98: China Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 99: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 100: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 101: China Population ages 65 and above (% of Total Population), 2016-20

Figure 102: China Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 103: China Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 104: China Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 105: Japan Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 106: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 107: Japan Current Healthcare Expenditure as a percentage of GDP, 2015-2018 (In %)

Figure 108: Japan Population ages 65 and above (% of Total Population), 2016-20

Figure 109: Japan Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 110: Japan Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 111: Japan Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026

Figure 112: India Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)

Figure 113: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 114: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 115: India Population ages 65 and above (% of Total Population), 2016-20

Figure 116: India Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026

Figure 117: India Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 118: India Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026

Figure 119: Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Drug Type (2016-2026)

Figure 120: Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Treatment (2016-2026)

Figure 121: Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Diagnosis (2016-2026)

Figure 122: Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Region (2016-2026)

Figure 123: Global Rheumatoid Arthritis Market - Company Share (%), 2020

Figure 124: Merck KGaA Sales Revenues, 2016-2020 (USD Million)

Figure 125: Merck KGaA Gross Profit, 2016-2020 (USD Million)

Figure 126: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020

Figure 127: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020

Figure 128: Sanofi Sales Revenues, 2016-2020 (USD Million)

Figure 129: Sanofi Gross Profit, 2016-2020 (USD Million)

Figure 130: Sanofi Sales Revenue Split, By Business Segment (%), FY2020

Figure 131: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020

Figure 132: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020

Figure 133: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020

Figure 134: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020

Figure 135: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020

Figure 136: Amgen Inc. Sales Revenues, 2016-2020 (USD Million)

Figure 137: Amgen Inc. Net Income, 2016-2020 (USD Million)

Figure 138: Amgen Inc. Sales Revenue Split, By Business Segment (%), FY2020

Figure 139: Amgen Inc. Sales Revenue Split, By Geography Segment (%), FY2020

Figure 140: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)

Figure 141: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)

Figure 142: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020

Figure 143: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020

Figure 144: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)

Figure 145: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)

Figure 146: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020

Figure 147: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020

Figure 148: Johnson & Johnson Annual Sales Revenue (USD Billion), 2016-2020

Figure 149: Johnson & Johnson Annual Net Income/Loss (USD Billion), 2016-2020

Figure 150: Johnson & Johnson Sales Revenue Split, By Business Segment (%), FY2020

Figure 151: Johnson & Johnson Sales Revenue Split, By Geography Segment (%), FY2020

Figure 152: Cipla Sales Revenues, 2016-2020 (USD Million)

Figure 153: Cipla sales Revenues, By Business Segment (%), FY2020

Figure 154: Cipla sales Revenue, By Geographical Segment (%), FY2020

Figure 155: Pfizer Annual Sales Revenue (USD Million), 2016-2020

Figure 156: Pfizer Annual Net Income/Loss (USD Million), 2016-2020

Figure 157: Pfizer sales Revenue, By Geographical Segment (%), FY2020

Figure 158: Galapagos NV Annual Sales Revenue (USD Million), 2016-2020

Figure 159: Galapagos NV sales Revenue, By Geographical Segment (%), FY2020

Figure 160: Gilead Sciences Annual Sales Revenue (USD Million), 2016-2020

Figure 161: Gilead Sciences Annual Net Income (USD Million), 2016-2019